Literature DB >> 22480951

Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease.

Hak-Ryul Kim1, Chang-Duk Jun, Koung-Sun Lee, Ji-Hyun Cho, Eun-Taik Jeong, Sei-Hoon Yang, Young-Jin Lee, Do-Sim Park.   

Abstract

BACKGROUND: YKL-40 (a chitinase-like protein) is an inflammatory biomarker that is associated with lung injury pathogenesis. We aimed to identify the diagnostic values of YKL-40 in pleural effusions and to evaluate circulating YKL-40 levels during multiple etiological pulmonary/pleural diseases and the role of YKL-40 as a monitoring marker of inflammatory pulmonary disease.
METHODS: Pleural YKL-40 (n=197), YKL-39 (the most homologous chitinase-like protein to human YKL-40), and conventional pleural marker levels were measured in patients with pulmonary/pleural disease. Additionally, serum YKL-40 and YKL-39 levels were analyzed in both patients and controls (n=432) and serially monitored in patients with asthma (n=27) or pneumonia (n=22).
RESULTS: Pleural YKL-40 levels were higher than those in the serum and highest in tuberculous pleural effusions (TPEs; 1181 ng/mL), followed by parapneumonic, malignant, and cardiogenic effusions (560 ng/mL). The diagnostic accuracy of pleural YKL-40 (0.78) for discriminating between tuberculous and malignant effusion was comparable to or greater than those of YKL-39, total protein, C-reactive protein and CYFRA 21-1, and lower than those of adenosine deaminase (p<0.05) and carcinoembriogenic antigen (p=0.05). Serum YKL-40 levels were higher in the pneumonia group than in the cancer, asthma, or control groups. Following treatment, serum YKL-40 levels were more greatly reduced in pneumonia patients than in asthma patients. Serum YKL-39 levels did not differ between patients and controls.
CONCLUSIONS: Pleural YKL-40 levels are elevated in TPEs and have fairly good diagnostic efficacy for detecting TPEs. However, adenosine deaminase is more efficient for detecting TPEs than pleural YKL-40. Serum YKL-40 levels are highest during pneumonia compared to common pulmonary/pleural diseases and are more useful for monitoring pneumonia than asthma.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480951     DOI: 10.1016/j.cyto.2012.03.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  The clinical utility of pleural YKL-40 levels in diagnosing pleural effusions.

Authors:  Servet Kayhan; Aziz Gumus; Halit Cinarka; Naci Murat; Adnan Yilmaz; Recep Bedir; Unal Sahin
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 2.  Association between YKL-40 and asthma: a systematic meta-analysis.

Authors:  Yihan Jin; Jie Song; Fang Xu; Di Zhang; Jinfang He; Jiakun Zheng; Yanan Zhang; Jintong Li; Yikun Guo; Mengjiao Xu; Xiangfeng Yu; Yanbin Liu; Qinghua Liu; Jun Yan
Journal:  Sleep Breath       Date:  2021-10-16       Impact factor: 2.655

3.  Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients.

Authors:  Hsiang-Ling Wang; Pei-Ching Hsiao; Hsiu-Ting Tsai; Chao-Bin Yeh; Shun-Fa Yang
Journal:  Int J Mol Sci       Date:  2013-11-19       Impact factor: 5.923

4.  Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study.

Authors:  Tonia Adamidi; Nikolaos Soulitzis; Eirini Neofytou; Savvas Zannetos; Andreas Georgiou; Kleomenis Benidis; Alexis Papadopoulos; Nikolaos M Siafakas; Sophia E Schiza
Journal:  BMC Pulm Med       Date:  2015-12-01       Impact factor: 3.317

Review 5.  The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review.

Authors:  Xiang Tong; Dongguang Wang; Sitong Liu; Yao Ma; Zhenzhen Li; Panwen Tian; Hong Fan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-30

6.  The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases.

Authors:  Ines Mack; Andreas Hector; Marlene Ballbach; Julius Kohlhäufl; Katharina J Fuchs; Alexander Weber; Marcus A Mall; Dominik Hartl
Journal:  Mol Cell Pediatr       Date:  2015-02-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.